Taurine (Amino Acid) : Physiology, Evidence, and Clinical Translation

Taurine: The Uncoupling Osmolyte at the Crossroads of Energy and Longevity

Taurine, or 2-aminoethanesulfonic acid, occupies a unique biochemical category. It is not incorporated into proteins; it is not oxidized for fuel; it is not a classical neurotransmitter, though it modulates neural excitability. Instead, it functions as a ubiquitous, high-concentration intracellular osmolyte and a multi-system cytoprotective agent. Its biology is defined by a set of paradoxical properties: it stabilizes membranes while facilitating calcium handling, it conjugates bile acids to promote fat absorption while lowering cholesterol, and its tissue concentration is highest in the most electrically and metabolically active organs, the heart, retina, and brain. Recent work has elevated taurine from a conditionally essential nutrient for infant formula to a central factor in the biology of aging, with declining tissue levels identified as a potential driver of the aging process itself. This analysis is written for the reader who must disentangle taurine's pleiotropic effects from the simplistic categorization of it as a minor ingredient in energy drinks. We dissect the mechanisms, grade the evidence, and map the critical unresolved questions.

---

Part 1. The Metabolic Divide: Why Endogenous Synthesis Is Insufficient for Long-Term Homeostasis

A meaningful discussion of taurine must begin with a quantitative metabolic fact: humans possess a limited biosynthetic capacity that was never designed to sustain a long post-reproductive lifespan. Taurine is synthesized primarily in the liver from cysteine via the cysteine sulfinic acid pathway, requiring cysteine dioxygenase and cysteine sulfinic acid decarboxylase, the latter being a pyridoxal 5'-phosphate-dependent enzyme. This pathway is constrained by a low enzymatic capacity in humans relative to rodents, and its activity is demonstrably downregulated with age, a phenomenon that is now a central target of gerontological investigation. In parallel, the dietary intake of taurine is virtually absent from a vegan diet, as it is found exclusively in animal-source foods such as meat, fish, and dairy. Omnivores consume 40 to 400 mg per day, a range that reflects the wide variance between a low-meat and a high-seafood diet.

This creates a nutritional landscape where the combined output of endogenous synthesis and diet can fail to meet the long-term demands for tissue maintenance. The heart, retina, and brain do not synthesize taurine; they import it against a massive concentration gradient via the TauT transporter. A chronic, subclinical deficit in supply forces these organs to operate with a depleted intracellular buffer, a state that does not trigger an acute deficiency syndrome but progressively degrades the resilience of electrically excitable and oxidatively stressed tissues over decades. The key variable is not the plasma concentration, which is defended by transporter-mediated homeostasis, but the chronic adequacy of supply to prevent a slow decline in tissue pools, a decline that is now directly measured in aging humans.

1A. A Clinical Taxonomy of Taurine Insufficiency Across Organ Systems

Taurine insufficiency can be classified into three mechanistic categories. A normal plasma level is a poor proxy for tissue adequacy, especially in the aged myocardium and retina, where transporter kinetics and declining renal reabsorption create a chronic intracellular deficit.

Absolute Supply-Side Insufficiency. This arises from a combination of low dietary intake and limited synthesis. Strict veganism is the most overt clinical scenario, producing lower plasma taurine concentrations and urinary excretion compared to omnivores. This state is magnified by co-factor deficiencies: the cysteine sulfinic acid decarboxylase enzyme requires pyridoxal 5'-phosphate. A functional B6 deficiency, whether nutritional or drug-induced, such as by isoniazid or oral contraceptives, directly impairs endogenous taurine synthesis. Infants are obligate dietary taurine consumers due to negligible synthetic capacity, a fact that drives its universal inclusion in human infant formula.

Kinetic Insufficiency: Adequate for Rest, Inadequate for Function. This is the chronic state of diminished tissue pools with aging. Longitudinal metabolomics shows a progressive decline in blood taurine concentration across the lifespan. The mechanism is a combination of decreased hepatic synthesis and, critically, a decline in renal reabsorption. The kidney's proximal tubule is responsible for reclaiming filtered taurine, and its efficiency falters with age. The consequence is a persistent, low-grade taurine leak that slowly depletes the intracellular reservoir in tissues dependent on the TauT transporter. This manifests not as catastrophic organ failure, but as a gradual decline in contractile reserve, retinal adaptability, and metabolic control, phenotypes that are commonly attributed to normal senescence.

Pathological Demand Surge. A previously compensated kinetic insufficiency can decompensate under conditions of acute or chronic metabolic stress. Chemotherapy with agents like cisplatin or doxorubicin generates a massive oxidative load and is directly toxic to the TauT transporter in renal tubules, causing a profound taurine wasting syndrome. Severe trauma, burns, and sepsis consume taurine through neutrophil myeloperoxidase activity, which uses taurine to generate taurine chloramine, a long-lived oxidant scavenger. This protective consumption can deplete plasma and tissue pools, leaving the heart and vasculature exposed to unopposed oxidative stress at a time of maximum vulnerability.

The consequences of these deficiency states propagate across every major organ system.

Neurological. Taurine is not a primary neurotransmitter but a potent modulator. It is a partial agonist at GABA-A and glycine receptors, providing a tonic inhibitory tone that stabilizes neuronal firing. In the developing brain, taurine deficiency impairs neuronal migration and synaptogenesis via its role as an osmolyte regulating cell volume in migrating neuroblasts. In the adult, a chronic insufficiency degrades the inhibitory surround that sharpens sensory processing, potentially manifesting as increased seizure susceptibility in models of temporal lobe epilepsy and heightened anxiety states. Taurine's role in the retina is non-redundant; photoreceptor outer segments are maintained by taurine's osmolytic and antioxidant functions, and a deficit leads to retinal degeneration in cats and non-human primates. The human correlate is a slow degradation of scotopic vision and photoreceptor resilience.

Cardiovascular and Circulatory. The heart maintains a taurine concentration gradient of approximately 200:1 over plasma, the steepest of any amino acid in any tissue. Taurine directly modulates cardiac contractility by altering the sensitivity of the myofilaments to calcium. A taurine-depleted heart exhibits systolic dysfunction under stress. Taurine is also a primary endogenous antagonist of angiotensin II signaling. It attenuates angiotensin II-induced vasoconstriction, cardiac hypertrophy, and fibrosis. An insufficiency removes this tonic brake, promoting a pro-hypertensive state and facilitating maladaptive cardiac remodeling independent of the classical pressure-overload pathways. The epidemiological association of higher urinary taurine with lower cardiovascular mortality in Japanese cohorts is mechanistically grounded in this dual role in calcium handling and neurohormonal antagonism.

Immunological. Activated neutrophils use taurine as a sacrificial substrate. Myeloperoxidase oxidizes taurine to taurine chloramine, which is more stable and less indiscriminate than hypochlorous acid itself. Taurine chloramine functions as a signaling molecule, downregulating NF-kB, tumor necrosis factor-alpha, and interleukin-6 expression in macrophages. A taurine deficit deprives the innate immune system of this endogenous anti-inflammatory effector, promoting a state of chronic, low-grade inflammation that is distinct from acute infection but metabolically destructive. This positions taurine as an essential component of the resolution phase of inflammation, not its initiation.

Respiratory. The airway epithelium is exposed to a continuous barrage of inhaled oxidants. Taurine chloramine is produced by the airway epithelium as a frontline defense against ozone, nitrogen dioxide, and the oxidative burst of recruited neutrophils. A taurine deficit reduces the capacity of the epithelial lining fluid to neutralize these insults, promoting airway hyperreactivity. There is mechanistic plausibility that chronic taurine insufficiency in the airway contributes to the exacerbation-prone phenotype in asthma and chronic obstructive pulmonary disease, where a failure to quench oxidative cascades leads to sustained bronchoconstriction and matrix degradation.

Integumentary. Taurine is a dominant osmolyte in the epidermis, where it regulates keratinocyte hydration and survival under UV-induced osmotic and oxidative stress. A deficit impairs the skin's ability to maintain cell volume and antioxidant defenses during UV exposure, accelerating photoaging. Taurine's anti-fibrotic properties, mediated via inhibition of transforming growth factor-beta signaling, are relevant to wound healing; an insufficiency may promote hypertrophic scarring and excessive fibrosis. Topical taurine is an active area of investigation in cosmeceutical science for barrier repair.

Musculoskeletal and Structural Integrity. Skeletal muscle is a quantitatively significant taurine reservoir. Taurine modulates the excitation-contraction coupling apparatus by regulating the sarcoplasmic reticulum calcium release channel, the ryanodine receptor. A deficiency leads to impaired calcium release, reduced force generation, and accelerated fatigue. The muscle atrophy of aging, sarcopenia, is associated with a decline in muscle taurine content. Taurine supplementation in aged mice restores muscle function and reduces mitochondrial oxidative stress, providing a mechanistic link between taurine insufficiency and the loss of physical function with age. In bone, taurine stimulates osteoblast differentiation and suppresses osteoclast activity via its antioxidant and anti-inflammatory effects, making it a potential modulator of postmenopausal bone loss.

Metabolic: Energy, Glucose, and Body Weight. Taurine is concentrated in the mitochondria of most cells, where it covalently modifies a specific leucine transfer RNA in the mitochondrial genome, a modification essential for the translation of ND6, a core subunit of Complex I of the electron transport chain. A taurine deficit directly impairs mitochondrial Complex I function, reducing oxidative phosphorylation efficiency and shifting metabolism toward glycolysis. This mitochondrial mechanism is now a leading hypothesis to explain the robust association between taurine insufficiency and the metabolic syndrome: low plasma taurine predicts incident diabetes, and taurine supplementation in animal models of obesity reduces body weight gain, improves glucose tolerance, and prevents diet-induced insulin resistance. The pancreatic beta-cell is a direct target; taurine protects against glucotoxicity and cytokine-induced apoptosis, preserving insulin secretory capacity.

Endocrine and Reproductive. Taurine directly modulates the hypothalamic-pituitary axis. It suppresses sympathetic nervous system outflow by acting on GABA-A receptors in the paraventricular nucleus, reducing corticotropin-releasing factor release and blunting the adrenocorticotropic hormone and cortisol response to stress. A deficiency removes this central anxiolytic brake, promoting an exaggerated stress response. In the thyroid axis, taurine protects thyrocytes from oxidative damage during hormone synthesis, where hydrogen peroxide is generated in high quantities. A deficit may accelerate thyroid follicular cell damage in autoimmune thyroiditis.

In the male reproductive system, taurine is present in spermatozoa and seminal fluid at very high concentrations. It functions as an osmolyte protecting sperm motility and as an antioxidant shielding sperm DNA from oxidative fragmentation. A deficiency is associated with asthenozoospermia and reduced fertility. In females, taurine protects ovarian follicles from oxidative atresia, and its follicular fluid concentration correlates with oocyte quality in in vitro fertilization cycles.

Excretory and Detoxification: The Kidney and Bile Acid Conjugation. The kidney is the master regulator of systemic taurine status. The proximal tubule TauT transporter reclaims over 95% of filtered taurine. Renal disease, cisplatin toxicity, and aging impair this reclamation, leading to hypertaurinuria and systemic depletion. This is a vicious cycle: a depleted kidney has diminished taurine for its own cytoprotection, rendering it more vulnerable to nephrotoxic and ischemic injury.

Taurine is the sole amino acid conjugated to bile acids by the liver, forming taurocholate. This conjugation reduces the pKa of the bile acid, ensuring it remains ionized and trapped in the biliary tree for fat emulsification. A taurine deficit shifts the conjugation ratio toward glycine, which produces glycocholic acids that are more hydrophobic and potentially more toxic to hepatocytes. Moreover, taurine conjugation is a primary pathway for cholesterol elimination; a deficit may contribute to cholesterol supersaturation of bile, increasing lithogenicity and the risk of gallstone formation. The enterohepatic circulation of bile acids, deconjugated by gut bacteria, liberates taurine in the colon, which serves as an energy substrate for specific sulfate-reducing bacteria, directly linking taurine intake to the composition and metabolic output of the gut microbiome.

Hepatic Structure: Steatosis and Fibrosis. Taurine deficiency promotes hepatic steatosis through mitochondrial dysfunction. Impaired Complex I activity reduces fatty acid oxidation and increases lipid peroxidation. Taurine's role in bile acid conjugation also means a deficit impairs reverse cholesterol transport and bile flow, exacerbating intrahepatic lipid accumulation. Supplementation in models of non-alcoholic steatohepatitis reduces steatosis, inflammation, and fibrosis. The anti-fibrotic effect is directly linked to taurine's ability to inhibit hepatic stellate cell activation, the same transforming growth factor-beta antagonism observed in the skin, positioning it as a potential multi-organ anti-fibrotic agent.

Homeostatic, Repair, and Rebalancing Systems. The unifying theme across all organ systems is the erosion of cytoprotective capacity. Taurine sufficiency is not a binary state; it is a continuous variable that determines the cell's ability to regulate its volume, buffer calcium, defend against oxidants, and maintain mitochondrial energy output. A kinetic insufficiency degrades the myocardium's contractile reserve, the neuron's inhibitory tone, the kidney's resistance to toxins, and the beta-cell's capacity to withstand glucotoxicity, all simultaneously. The clinical phenotype is a global decline in physiological adaptability that accelerates the aging trajectory of the most metabolically demanding tissues.

---

Part 2. The Tripartite Mechanism: Osmolyte, Mitochondrial Modulator, and Anti-Inflammatory

The function of taurine in mammalian tissues operates through three conceptually distinct but functionally integrated mechanisms.

Osmotic Regulation and Cell Volume Control. This is taurine's most ancient and fundamental role. In response to cell swelling, taurine is released via volume-sensitive anion channels to decrease intracellular osmolarity and restore normal volume. In response to cell shrinkage, the TauT transporter is upregulated to reaccumulate taurine. This osmotic cycle is essential for neurons undergoing firing-induced swelling, cardiac myocytes during systole, and renal medullary cells exposed to extreme osmotic gradients. Taurine's inertness, it is not metabolized and carries no charge at physiological pH, makes it the ideal osmolyte, as its movement does not perturb membrane potential or metabolic pathways.

Mitochondrial Quality Control and Energetics. The discovery of taurine's conjugation to mitochondrial leucine tRNA places it at the heart of respiratory chain biogenesis. Beyond this, taurine buffers the mitochondrial matrix against calcium overload, preventing the opening of the mitochondrial permeability transition pore, the terminal executioner of cellular apoptosis during ischemia-reperfusion injury. It also directly scavenges reactive oxygen species, particularly hypochlorous acid, forming taurine chloramine, a less reactive oxidant that can be reduced back to taurine. This mitochondrial nexus defines taurine's role in the heart, muscle, and brain.

Anti-Inflammatory and Anti-Fibrotic Signaling. Taurine chloramine is not merely a waste product; it is a signaling molecule. It inhibits the NF-kB pathway by oxidizing I-kB kinase, preventing the phosphorylation and degradation of the NF-kB inhibitor. This mechanism suppresses the transcriptional program of inflammatory cytokines and adhesion molecules. In parallel, taurine inhibits transforming growth factor-beta signaling, the master regulator of fibrosis, by interfering with the SMAD pathway. This dual action on inflammation and fibrosis gives taurine its therapeutic profile in models of cardiovascular, pulmonary, hepatic, and renal fibrotic diseases.

---

Part 3. The Evidence Mapped by Quality and Mechanism

The clinical translation of taurine's biology is characterized by a massive body of animal model data and a smaller but growing set of human trials that are beginning to validate the mechanistic predictions.

3.1. Cardiovascular Hemodynamics: A Direct Antihypertensive and Inotropic Modulator

A meta-analysis of 12 randomized, placebo-controlled human trials concluded that taurine supplementation, typically at 1.5 to 6 grams per day, significantly reduces both systolic and diastolic blood pressure in prehypertensive and hypertensive individuals. The mechanism is a direct attenuation of angiotensin II signaling and an improvement in endothelial function via antioxidant mechanisms. In heart failure, a small but rigorous double-blind trial showed that 3 grams of taurine per day for two weeks improved left ventricular systolic function, as measured by echocardiographic ejection fraction and cardiopulmonary exercise testing, without adverse effects. These are direct translations of the calcium-handling and neurohormonal mechanisms established in preclinical models.

3.2. Metabolic Syndrome and Diabetes: Preserving Beta-Cell and Mitochondrial Function

Human observational data consistently link low plasma taurine to incident type 2 diabetes. Intervention trials are supportive but smaller. A daily dose of 3 grams of taurine for 8 weeks reduced hemoglobin A1C and fasting glucose in overweight, non-diabetic individuals, while a 12-week trial in type 2 diabetics showed significant reductions in serum fructosamine and insulin resistance indices compared to placebo. The strongest mechanistic evidence in humans is that taurine prevents the exercise-induced oxidative damage to DNA and lipids, and co-administration with branched-chain amino acids in patients with liver cirrhosis improves mitochondrial ATP production, measured via phosphorus-31 magnetic resonance spectroscopy, a direct in vivo confirmation of the mitochondrial hypothesis.

3.3. Visual and Retinal Function: The Photoreceptor Osmolyte

The retina is the most taurine-concentrated tissue in the body. Animal models of taurine deficiency produce a predictable photoreceptor degeneration. Human trials are sparse but mechanistically compelling. A study using 1.5 grams of taurine per day in patients with early diabetic retinopathy showed a partial reversal of retinal electrophysiological deficits, specifically in the b-wave amplitude of the electroretinogram, indicating preserved inner retinal function. This aligns with taurine's role in protecting retinal ganglion cells and photoreceptors from hyperglycemic and oxidative injury. A postulation requiring rigorous investigation is whether lifelong taurine insufficiency accelerates age-related macular degeneration.

3.4. The Longevity Connection: Reversing the Aging Decline

The most provocative and consequential human data are emerging from geroscience. A landmark 2023 study in Science demonstrated that taurine concentration declines with age in mice, monkeys, and humans, and that supplementing aged mice with taurine extended median lifespan by 10 to 12%, while also improving bone density, muscle strength, immune function, and glucose tolerance. While a human lifespan trial is not feasible, the study's demonstration that taurine supplementation reversed multiple aging hallmarks in a non-human primate model provides the most rigorous preclinical evidence to date that the age-related decline in endogenous taurine synthesis is a driver, not a passenger, of the aging process. Small human pilot studies on mitochondrial function in aging muscle and liver are consistent with this framework but are underpowered for longevity endpoints.

---

Part 4. A Clinical Dosing Compendium: Evidence-Based Protocols and Theoretical Frameworks

The therapeutic application of taurine is determined by the physiological target. Taurine has a wide therapeutic window, is well-tolerated up to 6 grams per day in most individuals, and does not cause osmotic diarrhea due to its unique renal and intestinal handling.

4.1. Evidence-Based Protocols: Dosing with Published Human Data

Cardiovascular Risk: Hypertension and Heart Failure. The target is the attenuation of angiotensin II-mediated vasoconstriction and the stabilization of myocardial calcium handling. The evidence supports a total daily dose of 3 to 6 grams, divided into two or three doses with meals to sustain a therapeutic plasma elevation. For hypertension, 3 grams per day is a reasonable starting dose, titrated to blood pressure response over 4 weeks. For stable, compensated heart failure with reduced ejection fraction, a dose of 3 grams per day in divided doses has demonstrated echocardiographic benefit. Taurine is not a substitute for guideline-directed medical therapy; it is an adjunct that addresses the redox and calcium vulnerability not targeted by standard pharmacotherapy.

Metabolic Syndrome and Type 2 Diabetes. The goals are mitochondrial support, beta-cell protection, and reduction of oxidative stress. The evidence-based dose is 3 grams per day, divided into three 1-gram doses taken with meals. The co-administration with meals is mechanistically sound: it delivers taurine during the postprandial glucose and lipid surge when mitochondrial and endothelial oxidative stress is maximal. A duration of 8 to 12 weeks is required to see changes in glycemic indices.

Exercise-Associated Muscle Damage and Recovery. Taurine mitigates exercise-induced oxidative damage and calcium overload in myocytes. A protocol of 1 to 2 grams, taken 60 to 90 minutes before intense or prolonged exercise, combined with a post-exercise dose of 1 gram with a recovery meal, has been shown to reduce markers of muscle damage, including creatine kinase and lactate dehydrogenase, and to attenuate DNA oxidative damage in athletes.

4.2. Theoretical and Postulated Dosing Frameworks for Future Investigation

These strategies are derived from mechanism. They have not been validated in human outcome trials and are presented as hypotheses for clinical researchers.

Age-Related Sarcopenia and Physical Function. Rationale: muscle taurine content declines with age, impairing calcium release and mitochondrial function. Postulate: a daily dose of 3 grams, combined with a protein-rich meal and resistance exercise, may enhance muscle protein synthesis, improve mitochondrial biogenesis, and preserve muscle power in individuals over 65. The primary endpoint should be muscle taurine content by magnetic resonance spectroscopy, muscle power by dynamometry, and mitochondrial function by phosphocreatine recovery time.

Cisplatin and Aminoglycoside-Induced Ototoxicity and Nephrotoxicity. Rationale: cisplatin directly impairs the TauT transporter, depleting intracellular taurine and potentiating oxidative damage in the cochlea and proximal tubule. Postulate: a loading dose of 3 grams of taurine intravenously or orally one hour before chemotherapy infusion, followed by 3 grams per day in divided doses for one week post-cycle, may reduce the incidence of high-frequency hearing loss and nephrotoxicity. Audiometry, serum creatinine, and urinary kidney injury molecule-1 should serve as endpoints. This strategy must be designed to not interfere with the anti-neoplastic efficacy of the chemotherapy.

Gallstone Prevention in Rapid Weight Loss. Rationale: during rapid weight loss, biliary cholesterol saturation increases. Taurine conjugation of bile acids reduces cholesterol crystallization. Postulate: in patients undergoing bariatric surgery or a very low-calorie diet, a daily dose of 1.5 grams of taurine may reduce the incidence of de novo gallstone formation. The endpoint should be serial gallbladder ultrasound at 6 and 12 months.

Retinitis Pigmentosa and Inherited Photoreceptor Degeneration. Rationale: photoreceptors are metabolically expensive cells with an extraordinary demand for taurine as an osmolyte and antioxidant. Postulate: a high-dose regimen of 4 to 6 grams per day, sustained for a minimum of 12 months, may slow the rate of visual field decline in specific genetic subtypes. The primary endpoint must be Goldmann visual field area and full-field electroretinogram amplitude. This is a disease-modifying, not a curative, hypothesis.

4.3. Universal Principles Governing Taurine Dosing

Several principles transcend the specific indication.

Tissue Loading Requires Time. Taurine's clinical effects are not instantaneous. Intracellular taurine pools, particularly in the heart and muscle, have a slow turnover. While acute vascular effects on blood pressure may be seen within weeks, structural and metabolic effects on cardiac remodeling, retinal function, and muscle performance require a consistent daily intake over a minimum of three to six months to reach a new steady-state tissue concentration.

The Renal Axis Is Central. Taurine dosing is self-regulating via the kidney. In states of sufficiency, excess taurine is excreted in the urine. In deficiency, renal reabsorption is upregulated. This biological feedback makes taurine remarkably safe and resistant to acute toxicity. Monitoring a 24-hour urinary taurine excretion is a direct window into total body status and can guide dosing: a low urinary taurine confirms systemic insufficiency and the need for repletion.

Combine with Meals for Metabolic Targets. For cardiometabolic indications, taurine should be taken with meals. This synchronizes its peak plasma concentration with the postprandial state, when it can directly buffer the glucose- and lipid-induced oxidative burst and protect the endothelium.

Synergy with Magnesium and Omega-3s. Taurine's effects on calcium handling and membrane stabilization are synergistic with magnesium, a physiological calcium antagonist. Combining taurine with marine omega-3 fatty acids, which also target the resolution of inflammation via distinct resolvin pathways, is a mechanistically sound, though untested, strategy for comprehensive cardiovascular risk reduction.

---

Part 5. The Unresolved Frontier

Three open questions define the current scientific uncertainty around taurine.

Is Taurine a Geroprotective Molecule in Humans? The demonstration that taurine supplementation extends healthspan and lifespan in mice and non-human primates is among the most compelling anti-aging findings in recent biology. The human data are confined to biomarkers. The central unsolved problem is whether restoring taurine levels to youthful concentrations in middle-aged humans will directly modify the trajectory of multisystem decline. A TAME-like (Targeting Aging with Metformin) randomized trial of taurine is required, with a primary composite endpoint of incident cardiovascular events, cancer, cognitive decline, and mortality.

What Is the Role of Taurine in Cancer Biology? Taurine's anti-inflammatory and antioxidant profile suggests a chemopreventive role, and high dietary intake is inversely associated with certain cancers. However, taurine's role as an osmolyte that supports cell proliferation and survival poses a theoretical concern in established malignancy. The metabolic fate of taurine within the tumor microenvironment, where it may be imported by cancer cells to buffer oxidative stress, remains a frontier that demands clarification before any recommendation in cancer survivors is made.

Can Taurine Correct a Subset of Treatment-Resistant Hypertension? The mechanism of taurine's inhibition of angiotensin II signaling is distinct from ACE inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists. It targets a redox-sensitive step in the synthesis of angiotensinogen. In patients with low-renin, salt-sensitive hypertension, often seen in African American and elderly populations, taurine supplementation may represent a novel, non-pharmacological strategy that directly addresses the underlying endothelial oxidative stress. A dedicated trial in this specific hypertensive endotype is required to test this mechanistically precise hypothesis.

---

Part 6. Synthesis for an Evidence-Based Approach

Taurine is a case study in the failure of reductionist categorization. It is not a proteinogenic amino acid, yet it is one of the most abundant amino acids in the human body. It is not a hormone, yet its decline with age triggers a degenerative cascade across organs. It is not a drug, yet its supplementation produces a clinically meaningful reduction in blood pressure and an improvement in cardiac function. Its biology is ancient, rooted in the osmotic regulation of primordial cells, and has been exquisitely adapted to the demands of the most complex tissues in modern mammals.

The clinical taxonomy of its deficiency reveals a progressive, age-dependent loss of cytoprotective capacity that manifests as a slow failure of the heart's contractile reserve, the beta-cell's insulin secretory capacity, the retina's photoreceptor integrity, and the muscle's mitochondrial efficiency. The evidence base is strongest for cardiovascular and metabolic applications, where dosing protocols of 3 to 6 grams per day provide a safe, evidence-based adjunct. The expanded dosing compendium offers researchers a structured map of the most mechanistically compelling, yet unproven, applications. The scientific frontier, however, lies in the hypothesis that taurine is an essential biochemical determinant of the rate of aging itself. The investigation of this hypothesis has moved taurine from a niche supplement for feline nutrition to a central molecule in the quest to understand and compress human morbidity.